Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Todd L. Saretsky"'
Autor:
Valerie Williams, Carla DeMuro Romano, Lyn Finelli, Shanshan Qin, Todd L. Saretsky, Jia Ma, Sandy Lewis, Matthew Phillips, Richard H. Osborne, Josephine M. Norquist
Publikováno v:
Health and Quality of Life Outcomes, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Despite a number of respiratory syncytial virus (RSV) vaccine candidates being tested in clinical trials, disease-specific, self-reported instruments assessing symptom severity of RSV infection from the perspective of adult patien
Externí odkaz:
https://doaj.org/article/529fe222041240c385c399d2f0052e83
Autor:
Amy M. Jones, Todd L. Saretsky, Charlotte Panter, Jane R. Wells, Frances White, Verity Smith, Helen Kendal, Kevin Russell, Madelyn Ruggieri, Shawna R. Calhoun, Adam Gater, Justin O’Hagan, Kathryn B. Anderson, Valerie A. Paz-Soldan, Amy C. Morrison, Lisa Ware, Michelle Klick, Stephen Thomas, Morgan A. Marks
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-18 (2023)
Abstract Background Dengue is the most prevalent arboviral infection causing an estimated 50–60 million cases of febrile illness globally per year, exacting considerable disease burden. Few instruments exist to assess the patient illness experience
Externí odkaz:
https://doaj.org/article/184c2e4578e846c188f7230c30975c5c
Autor:
Carla (DeMuro) Romano, Lyn Finelli, Sandy Lewis, Valerie Williams, Emily Martin, Matthew Phillips, Todd L. Saretsky, Josephine Norquist
Publikováno v:
Health and Quality of Life Outcomes, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Respiratory syncytial virus (RSV) causes significant morbidity and mortality in older adults. Despite a number of RSV vaccine candidates in clinical trials, there are no existing disease-specific, self-reported measures that asses
Externí odkaz:
https://doaj.org/article/afe382a223984a7f92f004327720f42c
Autor:
José Salvador Rodrigues de Oliveira, Guilherme Fleury Perini, Pier Luigi Zinzani, Valeria Buccheri, John Kuruvilla, Radhakrishnan Ramchandren, Nathalie A. Johnson, Ying Zhu, Todd L. Saretsky, Michael Dickinson, Armando Santoro, Andrew McDonald, Ewa Paszkiewicz-Kozik, Akash Nahar, Muhit Ozcan, Monika Raut, Naohiro Sekiguchi, Robin Gasiorowski
Publikováno v:
Blood Advances
Key Points Pembrolizumab improved health-related quality of life over brentuximab vedotin in patients with relapsed/refractory cHLPembrolizumab should be considered the preferred treatment option for relapsed/refractory cHL post-ASCT or in patients i
Autor:
Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Gafanov, Loic Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andre M. Bergman, Pawel Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell Kent Pachynski, Todd L. Saretsky, Sameer R. Ghate, Xin Tong Li, Charles Schloss, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 41:129-129
129 Background: The double-blind, phase 3, randomized KEYNOTE-921 trial (NCT03834506) showed that pembro + docetaxel did not significantly improve rPFS or OS for pts with mCRPC treated with prior next-generation hormonal agent (NHA) therapy. We prese
Autor:
Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Raymond S. McDermott, Nuria Sala González, Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Eduardo Yanez, Yi-Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, Todd L. Saretsky, Sameer R. Ghate, Yi Cui, Jeri Kim, Evan Y. Yu
Publikováno v:
Journal of Clinical Oncology. 41:131-131
131 Background: The phase 3, randomized KEYLYNK-010 trial (NCT03834519) of pembro + ola vs next-generation hormonal agent (NHA) abi or enza did not significantly improve rPFS or OS in molecularly unselected pts with mCRPC treated with prior NHA and d
Autor:
Richard W. Joseph, Frank Xiaoqing Liu, Qing Harshaw, Todd L. Saretsky, Alan S. Pickard, Scott J. Diede, Cynthia Macahilig, Alicia C. Shillington, Vaidehi Dave
Publikováno v:
Quality of Life Research
Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in
Autor:
Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L Saretsky, Rodolfo F Perini, Cixin Steven He, Kalgi Mody, David Cella
Publikováno v:
Lancet Oncol
BACKGROUND: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-r
Autor:
Robin Gasiorowski, Michael Dickinson, John Kuruvilla, Monika Raut, Nathalie A. Johnson, Armando Santoro, Valeria Buccheri, Muhit Ozcan, Alice McDonald, Hilde Giezek, Todd L. Saretsky, Ewa Paszkiewicz-Kozik, P. L. Zinzani, Akash Nahar, Guilherme Fleury Perini, Naohiro Sekiguchi, J. S. R. de Oliveira, Radhakrishnan Ramchandren
Publikováno v:
Hematological Oncology. 39
Autor:
Wenjun Zhong, Zaina P. Qureshi, Paulette Ceesay, Todd L. Saretsky, W. Joseph Herring, Christopher Lines
Publikováno v:
Sleep. 44:A150-A150
Introduction Full montage polysomnography (PSG) is the gold standard for the objective evaluation of sleep but is time consuming and inaccessible to most clinicians. A Clinician’s Global Impression of Severity (CGI-S) scale can be used in clinical